Launch of OptiMAL platform

AI SummaryClose X

Fusion Antibodies plc has officially launched its OptiMAL® platform for discovering novel human antibodies, incorporating a proprietary synthetic library and Mammalian Display technology, with the library and its design method protected by US patent no. US12378696 and pending international patents. This launch, presented at the Antibody Engineering and Therapeutics conference, signifies a key development for the company's pre-clinical antibody discovery and engineering services, aiming to accelerate the delivery of therapeutic antibodies to market.

Disclaimer*

UK 100

Latest directors dealings